Cipla v. Teva & Norton: Federal Circuit Remands Inhaler Dose Counter Appeal
Cipla Limited brought an infringement action against Teva Pharmaceutical Industries and Norton (Waterford) Limited over six US patents covering dose counter technology for metered-dose inhalers. After 557 days, the Federal Circuit granted a joint motion to remand the appeal back to the district court, with each side bearing its own fees and costs.
Six inhaler dose counter patents head back to district court
Cipla Limited, an Indian pharmaceutical company and holder of six US patents covering dose counter mechanisms for inhalers, filed this appeal at the Court of Appeals for the Federal Circuit on 4 August 2023. The defendants, Teva Pharmaceutical Industries Ltd. and its Irish subsidiary Norton (Waterford) Limited, were accused of infringing patents directed at anti-reverse rotation actuators and assembly methods for inhaler dose counters — technology critical to patient safety and regulatory compliance in metered-dose inhaler products.
The appeal concluded on 11 February 2025 when the Federal Circuit granted a joint motion filed by both parties to remand the case to the district court. No merits ruling was issued at the appellate level. Each side was ordered to bear its own attorneys’ fees and costs, a cost allocation that is consistent with a negotiated procedural resolution rather than a clear-cut win for either party. The remand returns the dispute to the originating district court for further proceedings.
The 557-day appellate duration without a merits decision suggests the parties may have reached a preliminary commercial or licensing understanding that made full appellate adjudication unnecessary, though the public record does not confirm this. The joint nature of the remand motion is notable: contested remand requests are relatively uncommon at the Federal Circuit, and the mutual cost-bearing arrangement suggests both sides agreed the most efficient path forward was to resolve remaining issues at the district level rather than pursue a full appellate ruling on the six asserted patents.
Filing to Case Remanded in 557 days
557-day appeal duration before joint remand motion granted
Joint remand granted: what the Federal Circuit’s order means for both parties
Joint remand returns case to district court without merits ruling
A joint motion to remand signals that both parties agreed to return the case to the district court rather than pursue an appellate decision on the merits. The Federal Circuit’s order grants that motion without ruling on infringement, validity, or any other substantive question. This preserves the district court’s jurisdiction to address outstanding issues and means the appellate record does not resolve the underlying patent dispute.
No appellate merits decisionCipla’s patents remain in play — no adverse Federal Circuit ruling
For Cipla, the remand is procedurally neutral at the appellate level: no court has ruled the asserted dose counter patents invalid or not infringed. The case returns to district court, where Cipla retains the ability to pursue infringement claims. However, the absence of a merits win means the patents have not been judicially strengthened at the appellate level either. The practical outcome for Cipla depends on what occurs at the district court level following remand.
Patents unresolved — litigation continuesTeva and Norton avoid appellate adverse ruling — exposure remains
Teva Pharmaceutical and Norton (Waterford) secured the return of the case to district court without the Federal Circuit ruling against them on infringement or patent validity. However, because no merits determination was made, their exposure under Cipla’s six dose counter patents is not eliminated. The mutual cost-bearing arrangement suggests neither party extracted significant leverage from the appellate proceedings, and the dispute will likely require further resolution at the district court level.
Infringement exposure unresolvedInhaler dose counter IP landscape remains unsettled after remand
The remand without a merits ruling leaves the enforceability of Cipla’s inhaler dose counter patent portfolio — six patents covering anti-reverse rotation actuators and assembly methods — legally unresolved. For competitors and product developers in the metered-dose inhaler sector, this suggests continued uncertainty around FTO for dose counter technologies. Companies designing around or licensing these patents should monitor district court proceedings closely for any substantive rulings on validity or claim scope.
FTO uncertainty persistsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Cipla Limited | Individual | Indian pharmaceutical company — holder of six US inhaler dose counter patentsSearch in Eureka ↗ |
| Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Teva Pharmaceutical Industries Ltd. and Norton (Waterford) Limited — generic inhaler manufacturersSearch in Eureka ↗ |
| Co-Defendant | Norton (Waterford) Limited | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Adam Berlin | Attorney | Counsel for Cipla LimitedSearch in Eureka ↗ |
| Plaintiff counsel | Anil Patel | Attorney | Counsel for Cipla LimitedSearch in Eureka ↗ |
| Plaintiff counsel | Harold Storey | Attorney | Counsel for Cipla LimitedSearch in Eureka ↗ |
| Plaintiff counsel | Peter Giunta | Attorney | Counsel for Cipla LimitedSearch in Eureka ↗ |
| Plaintiff law firm | K&L Gates, LLP | Law Firm | Representing Cipla LimitedSearch in Eureka ↗ |
| Defendant counsel | Ben Picozzi | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Benjamin M. Greenblum | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | David I. Berl | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Elise Baumgarten | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Kathryn Schleckser Kayali | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Ricardo Leyva | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant law firm | Williams & Connolly LLP | Law Firm | Representing Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order is purely procedural: it grants the joint motion to remand and allocates costs without adjudicating any substantive patent question. The phrase ‘each side to bear their own fees and costs’ is characteristic of a negotiated resolution rather than a litigated outcome, and suggests neither party had sufficient appellate leverage to demand cost-shifting. The order leaves the district court as the forum of record for resolving infringement and validity questions across all six asserted inhaler dose counter patents.
US10561808B2 — Inhaler dose counter with anti-reverse rotation actuator
The six asserted patents — US10561808B2, US10086156B2, US10022510B2, US10022509B2, US9463289B2, and US9808587B2 — collectively cover dose counter technology for metered-dose inhalers, with particular focus on anti-reverse rotation actuator mechanisms and assembly methods. These patents protect components that track the number of doses remaining in an inhaler, a feature with direct regulatory and patient safety significance under FDA labelling requirements for pressurised metered-dose inhalers. The portfolio spans multiple application numbers, suggesting a deliberate continuation filing strategy to build layered protection around the core technology.
Dose counter technology has become a significant area of patent activity in the inhaler device sector, particularly as generic manufacturers seek to replicate branded inhaler features at scale. Cipla’s multi-patent portfolio — spanning both device architecture and manufacturing methods — creates a broad enforcement perimeter that is difficult to design around without addressing each patent’s independent claims. For Teva and Norton, the inability to obtain a Federal Circuit merits ruling means these patents retain their full presumption of validity, maintaining competitive pressure on generic inhaler product lines that incorporate dose-counting functionality.
Should you run an FTO against Cipla’s inhaler dose counter patents?
Any company developing, manufacturing, or importing metered-dose inhalers with integrated dose counters into the US market should assess freedom-to-operate against this six-patent portfolio. The asserted patents cover both device-level architecture (anti-reverse rotation actuators) and assembly methods, meaning both OEMs and contract manufacturers may face independent exposure. With no invalidity or non-infringement finding on the record, all six patents remain fully enforceable presumptively, and Cipla has demonstrated willingness to litigate through the Federal Circuit level.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map their inhaler dose counter designs against the claim language of all six Cipla patents simultaneously. Eureka can identify claim elements that overlap with your product architecture, flag continuation applications that may extend the portfolio’s reach, and surface prior art that could support validity challenges if licensing negotiations fail. Running an FTO now — before district court proceedings produce further rulings — provides the clearest window for informed design decisions.
Run a freedom-to-operate analysis on US10561808B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit inhaler device patent infringement cases
Explore Federal Circuit appeals involving inhaler device patents and pharmaceutical dose counter technology, including comparable infringement actions against generic manufacturers.
What this case signals for the inhaler device IP landscape
Six patents, two major pharmaceutical defendants, and a Federal Circuit remand — the dose counter technology dispute is far from over.
Joint remand at Federal Circuit often signals behind-the-scenes negotiation
When both parties jointly move to remand an appeal, it typically signals that settlement discussions or licensing negotiations are underway or have produced a preliminary agreement. The mutual cost-bearing order reinforces this reading. IP teams monitoring Cipla’s enforcement strategy should track district court filings post-remand for confirmation of any licensing terms or consent judgments.
Cipla’s six-patent portfolio creates layered FTO risk for inhaler manufacturers
With six asserted patents covering dose counter mechanisms and anti-reverse rotation actuators, Cipla has constructed a multi-layered IP position in the inhaler device space. No patent has been found invalid or not infringed in this proceeding. Manufacturers and component suppliers developing metered-dose inhaler dose counters should conduct FTO analysis across all six patent numbers before commercialisation.
Limited v Teva — key questions answered
The Federal Circuit granted a joint motion by both parties to remand the appeal to the district court. No merits ruling was issued on infringement or patent validity. Each party was ordered to bear its own fees and costs. The case was closed on 11 February 2025 after 557 days.
Cipla asserted six US patents: US10561808B2, US10086156B2, US10022510B2, US10022509B2, US9463289B2, and US9808587B2. These patents cover dose counter mechanisms for metered-dose inhalers, including anti-reverse rotation actuators and assembly methods.
A joint remand returns the case to the district court without any appellate ruling on the merits. The asserted patents retain their full presumption of validity. No infringement or non-infringement finding is made at the appellate level, and the district court resumes jurisdiction over the dispute.
Norton (Waterford) Limited is Teva’s Irish manufacturing subsidiary. Its inclusion as a co-defendant suggests Cipla’s infringement allegations extended to the manufacturing level, not only to commercial distribution of the accused inhaler products in the US market.
Because the Federal Circuit issued no invalidity or non-infringement ruling, all six Cipla dose counter patents remain presumptively valid and enforceable. Third-party inhaler manufacturers and component suppliers should conduct FTO analysis against these patents before commercialising dose counter technology in the US market. The remand also means further district court rulings on claim scope could emerge.
PatSnap Eureka searches patents and litigation data to answer instantly.